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IL-10R2 is a shared cell surface receptor required
for the activation of five class 2 cytokines (IL-10,
IL-22, IL-26, IL-28, and IL-29) that play critical roles
in host defense. To define themolecularmechanisms
that regulate its promiscuous binding, we have
determined the crystal structure of the IL-10R2 ecto-
domain at 2.14 A˚ resolution. IL-10R2 residues
required for binding were identified by alanine scan-
ning and used to derive computational models of
IL-10/IL-10R1/IL-10R2 and IL-22/IL-22R1/IL-10R2
ternary complexes. The models reveal a conserved
binding epitope that is surrounded by two clefts
that accommodate the structural and chemical
diversity of the cytokines. These results provide a
structural framework for interpreting IL-10R2 single
nucleotide polymorphisms associated with human
disease.
INTRODUCTION
IL-10R2 is a ubiquitously expressed and essential receptor chain
for at least five IL-10 family cytokines that share 10%–20%
sequence identity and distinct 3D structures (Donnelly et al.,
2004; Walter, 2004). IL-10R2, first called CRF2-4, was originally
discovered as an essential component of the IL-10 heterodi-
meric signaling complex formed between the IL-10R1 chain
and IL-10R2 (Kotenko et al., 1997). Solution and cell binding
studies have shown that IL-10R1 exhibits high affinity (nanomo-
lar) for IL-10, whereas IL-10R2 chain affinity is very low (approx-
imately millimolar) (Ding et al., 2000; Logsdon et al., 2002; Yoon
et al., 2005, 2006). IL-10-mediated assembly of the IL-10R1/
IL-10R2 complex activates intracellular kinases JAK1 and
TYK2, which phosphorylate the intracellular domains of the
receptor as well as STAT3 (Moore et al., 2001). Subsequent
studies have revealed IL-10R2 also forms IL-22R1/IL-10R2
(Kotenko et al., 2001; Xie et al., 2000), IL-20R1/IL-10R2 (Sheikh
et al., 2004), and IL-28R1/IL-10R2 (Kotenko et al., 2003; Shep-638 Structure 18, 638–648, May 12, 2010 ª2010 Elsevier Ltd All rightpard et al., 2003) heterodimers that are activated by IL-22,
IL-26, and IL-28/ IL-29, respectively (see Figure S1 available
online). Thus, IL-10R2 functions as a common signaling chain
in the class 2 cytokine family, as observed for gp130, IL-2gc
(gc), and GM-CSF bc chains in the class 1 cytokine family
(Wang et al., 2009).
Cytokines that signal via IL-10R2 induce pleiotropic activities
that protect the host from overexuberant immune responses
and activate innate immunity programs in epithelial cells. IL-10
inhibits macrophage and dendritic cell function, prevents proin-
flammatory cytokine synthesis (e.g., TNF-a, IFN-g, IL-12, and
IL-1), and blocks antigen presentation (Moore et al., 2001). As
a result of its potent immunosuppressive functions, numerous
pathogens, including HIV, evade host immune responses by
increasing the production of cellular IL-10 (Blackburn and
Wherry, 2007; Redpath et al., 2001). In addition, cytomegalovirus
(CMV) and Epstein Barr virus express their own virally encoded
IL-10s (cmvIL-10 and ebvIL-10) that disrupt immune function
(Slobedman et al., 2009). IL-22, produced by TH17 cells, induces
epithelial cells to produce antimicrobial peptides (Liang et al.,
2006) but also exhibits protective functions in the gut, lung,
and liver (Radaeva et al., 2004; Zenewicz et al., 2007). IL-26 is
also produced by TH17 cells and upregulates proinflammatory
genes in intestinal epithelial cells, and its expression is increased
in active Crohn’s disease (Dambacher et al., 2009). Finally, IL-28
and IL-29 form the recently discovered type III interferon family
(Kotenko et al., 2003; Sheppard et al., 2003). IL-28 and IL-29
exhibit potent antiviral activities in keratinocytes and dendritic
cells and may play an important role in resolving hepatitis C
infection (Ge et al., 2009).
The molecular basis whereby IL-10R2 is able to form promis-
cuous receptor-ligand interactions is unknown. In addition,
single nucleotide polymorphisms (SNPs) in the IL-10R2 extracel-
lular domain are associated with hepatitis virus subtype B (HBV)
persistence (Frodsham et al., 2006), early-onset colitis (Glocker
et al., 2009), graft-versus-host disease related to transplant
rejection (Lin et al., 2005; Sivula et al., 2009), and systemic
sclerosis (Hikami et al., 2008), an autoimmune disease charac-
terized by fibrosis of skin and other organs. Thus, structure
function studies on IL-10R2 may be useful in understanding
SNPs that alter immune function and result in human disease.s reserved
Table 1. sIL-10R2 Data Collection, Phasing, and Refinement
Statistics
Crystal 1 Crystal 2
Space group P6 P6
Cell a,b 124.27 124.84
Cell c 83.70 84.22
Wavelength (A˚) 0.97934 (peak) 1.00000
Resolution 50–2.5 50–2.14
Highest resolution 2.59–2.50 2.22–2.14
Completeness (%) 100 (100) 97.5 (84.6)
Redundancy 10.8 (10.7) 11.0 (5.1)
I/s 72 (26) 50 (5.9)
Rsym (%) 7.1 (15.7) 7.1 (28.9)
Phasing statistics
# Se (SOLVE) 12
FOM (SOLVE) 0.48
FOM (CNS DM) 0.91
Refinement statistics
Resolution (A˚) 50–2.14
Highest resolution 2.14–2.16
Rwork (%) 21.0 (27.7)
No. of reflections (work) 38,362
Rfree (%) 23.9 (36.5)
No. of reflections (free) 2,016
Residues in model A: 20–220
B: 20–215
No. of protein atoms 3,284
No. of water atoms 212
No. of sulfate 10
No. of glycerol 1
Rmsd bond distance (A˚) 0.0085
Rmsd bond angles () 1.43
Average B factor (A˚2) 37.3
Ramachandran plot
Most favored (%) 88.1
Additionally allowed (%) 9.6
Generally allowed (%) 1.4
Disallowed (%) 0.8
Structure
Mechanism of Receptor Sharing by IL-10R2To define the molecular basis for promiscuous binding to
diverse cytokine complexes, the crystal structure of the soluble
extracellular IL-10R2 chain (sIL-10R2) has been determined at
2.14 A˚ resolution. A series of sIL-10R2 mutants were evaluated
for binding to three different binary complexes (BCs; IL-22/sIL-
22R1, cmvIL-10/sIL-10R1, and hIL-10/sIL-10R1) using trimolec-
ular surface plasmon resonance (SPR) assays. The binding data
provided input for computational docking studies to generate
IL-10 and IL-22 ternary complex (TC) models. These studies
reveal that IL-10R2 uses a central common binding epitope,
centered on Y82IL-10R2, which is surrounded by two clefts that
allow the IL-10R2 chain to scan the unique structures and chem-
istries of helices A andD on the cytokines. The studies reveal that
IL-10R2 shares a conserved recognition motif with gp130 andStructure 18,IL-2gc, suggesting a common origin for the promiscuous
class 1 and class 2 cytokine receptors. Despite these common
features, sIL-10R2 forms structurally and energetically distinct
contacts with IL-10/sIL-10R1 and IL-22/sIL-22R1 BCs, which
could assist in the prediction of IL-10R2 SNP function.RESULTS
Structure Determination
The sIL-10R2 chain crystallized in space group P6 with two
molecules (chain A and B) in the asymmetric unit (Figure S2).
Crystals of sIL-10R2 were first obtained from protein expressed
in insect cells where N-linked glycosylation sites N49sIL-10R2,
N68sIL-10R2, N102sIL-10R2, and N161sIL-10R2 were mutated to
glutamine (sIL-10R2NQ). sIL-10R2NQ binds to the IL-22/sIL-
22R1 complex with 2-fold weaker affinity (Kd = 14 mM) than
glycosylated sIL-10R2 (Kd = 7 mM) expressed in insect cells.
For phasing, sIL-10R2, containing a C106sIL-10R2 to Ser muta-
tion, was expressed in E. coli as a selenomethionine-labeled
protein and refolded from insoluble inclusion bodies. Larger
crystals, used for data collection and refinement (Table 1, crystal
2), were obtained with a sIL-10R2 double mutant (C106SsIL-10R2/
S126CsIL-10R2). The structure was solved by single-wavelength
anomalous diffraction phasing and refined at 2.14 A˚ resolution
to Rcryst and Rfree values of 21.0% and 23.9%, respectively
(Table 1). Electron density was observed for residues 20–220
in chain A and 20–215 in chain B. sIL-10R2 residue numbering
is based on the sequence found in the Uniprot database code
Q08334.
Structure of sIL-10R2 andComparisonwith High Affinity
R1 Chains
The overall structure of sIL-10R2 is similar to the previously
determined structures of sIL-10R1 and sIL-22R1 (Bleicher
et al., 2008; Jones et al., 2008; Josephson et al., 2001). sIL-
10R2 consists of two fibronectin type III domains (FBNIII) each
comprising seven b strands (Figure 1A). The N-terminal domain,
D1, and C-terminal domain, D2, adopt an interdomain angle of
approximately 95 (Figure S2, elbow angle), which is similar to
the high affinity sIL-10R1 and sIL-22R1 chains (Figure 1B;
Figure S2). As seen in Figure 1B, the overall domain orientations
of sIL-10R2 are closer to sIL-22R1 than sIL-10R1.
The sIL-10R2 b strands are connected by a series of loops
(L2–L6), which are predicted to mediate ligand binding (Fig-
ure 1A; Jones et al., 2008; Pletnev et al., 2005). sIL-10R2 L2
and L5 loops exhibit large structural differences compared to
L2 and L5 in the sIL-10R1 and sIL-22R1 chains (Figures 1B
and 2). L2sIL-10R2 adopts a b-hairpin structure that is two residues
shorter than observed for the L2 loops in sIL-10R1 and IL-22R1.
As a result, L2 residue Y59sIL-10R2 cannot form the canonical high
affinity ‘‘R1 like’’ interaction, which consists of tyrosine residues
on the L2 loops of the R1 chains (Y43sIL-10R1 and Y60sIL-22R1) that
insert into clefts formed by the AB loops of the cytokines in the
IL-10/sIL-10R1 and IL-22/sIL-22R1 complexes (Figure 1D)
(Bleicher et al., 2008; Jones et al., 2008; Josephson et al.,
2001). Thus, the conformation of sIL-10R2 L2 is consistent with
the low affinity of the sIL-10R2 chain for its various binding
partners.638–648, May 12, 2010 ª2010 Elsevier Ltd All rights reserved 639
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Figure 1. Structure of the sIL-10R2 Chain
(A) Ribbon diagram of the sIL-10R2 chain colored
by secondary structure with binding loops labeled.
Box shows the location of (E).
(B) Superposition of sIL-10R2 (colored as in A) with
sIL-10R1 (green) and sIL-22R1 (purple). Box shows
the location of (D).
(C) Location of aromatic residues on sIL-10R2.
(D) Comparison of the high affinity site 1 interaction
between sIL-10R1 Y43sIL-10R1 and the AB loop of
IL-10 (green) with the sIL-10R2 L2 loop and
Y59sIL-10R2 (yellow).
(E) Interaction network for K47sIL-10R2. Replace-
ment of K47sIL-10R2 with a glutamic acid is associ-
ated with persistent HBV infection (Frodsham
et al., 2006).
Structure
Mechanism of Receptor Sharing by IL-10R2The sIL-10R2 L5 loop forms a ‘‘thumb-like’’ structure that
extends away from the rest of the molecule (Figures 1A and 2).
Despite conformational differences at the tip of L5 in chains A
and B due to crystal contacts, both L5 loops exhibit the same
overall ‘‘thumb’’ structure (Figure S2). The novel conformations
of the sIL-10R2 L2 hairpin and L5 thumb give rise to two distinct
clefts (Figure 2). The first is formed between the L2 and L3 loops
(L2/3 cleft) and the second is between L3 and L5 (L3/L5 cleft).
In contrast to sIL-10R2, no clefts are found in the high affinity
IL-10R1 chain and only very small L2/L5 and L3/L5 clefts are
observed in sIL-22R1 (Figure 2). Interestingly, IL-22R1 is also
a shared receptor, which forms IL-22R1/IL-10R2 and IL-22R1/
IL-20R2 heterodimers (Dumoutier et al., 2001). These structural
features, combined with the presence of four surface-exposed
aromatic residues (Y59, Y82, Y140, and W143) on the L2, L3,
and L5 loops (Figure 1C), suggest the clefts may play an impor-
tant role in the promiscuous binding properties of sIL-10R2.
Identification of sIL-10R2 Residues Required
for Ternary Complex Formation
To identify sIL-10R2 residues required for promiscuous interac-
tions with structurally and chemically diverse cytokines, a SPR
assay was designed to evaluate the relative binding strength of
sIL-10R2 alanine mutants to hIL-10/sIL-10R1, cmvIL-10/sIL-
10R1, and IL-22/IL-22R1 BCs (Figure 3; Figures S3–S5). Of the
22 point mutants tested, only Y82AsIL-10R2 displayed drastically
reduced (10%–20% of sIL-10R2WT) binding to all three BCs640 Structure 18, 638–648, May 12, 2010 ª2010 Elsevier Ltd All rights reserved(Figure 3). Y59AsIL-10R2, located on the
L2 loop, is the only other mutant that
exhibited significantly reduced binding
[50% of wild-type (WT)] to all three
complexes, but to a lesser extent than
Y82AsIL-10R2. Other mutants disrupted
sIL-10R2 recognition of cmvIL-10/sIL-
10R1 and hIL-10/sIL-10R1 complexes
or IL-22/sIL-22R1 complexes, but not
both. For example, Y56AsIL-10R2 and
Y140AsIL-10R2 exhibit diminished binding
(20% of WT) to hIL-10/cmvIL-10
BCs, but had no impact on the recog-
nition of IL-22/sIL-22R1. In contrast,
W143AIL-10R2, and to a lesser extentE141IL-10R2, selectively disrupted IL-22/IL-22R1 recognition,
but not hIL-10/cmvIL-10/sIL-10R1 binding. Together, these
studies suggest L3 residue Y82sIL-10R2 provides a centrally
located common binding epitope, while different residues on
L2 and L5 make distinct energetic contributions to binding in
different BCs.
Six of the 22 sIL-10R2 mutants (Q119A, H128A, R130A,
L132A, K135A, and Y173A), located on b strands A, B, and E
of D2, targeted putative receptor-receptor contacts (Jones
et al., 2008; Pletnev et al., 2005) between the D2 of the R1 chains
and D2sIL-10R2. Y173AsIL-10R2 exhibited reduced binding (65% of
WT) to IL-22/IL-22R1 but did not reduce binding to cmvIL-10/
sIL-10R1 or hIL-10/sIL-10R1 complexes. The other five mutants
had no impact on IL-10R2 binding to any BC (data not shown).
Thus, from a limited analysis of D2 residues, we have not identi-
fied an essential sIL-10R2 residue (such as Y82sIL-10R2 described
above) involved in R1/R2 D2-D2 contacts. It is unclear if this
is due to the limited number of residues analyzed or specific
characteristics of the D2 binding interfaces themselves.
Generation of IL-10 and IL-22 Ternary Complexes
by Computational Docking
To further understand the mechanisms that allow promiscuous
IL-10R2 recognition, the mutagenesis data (Figure 3; Table S1)
(Logsdon et al., 2004; Wolk et al., 2004; Wu et al., 2008;
Yoon et al., 2006) was used to guide computer-based docking
of sIL-10R2 onto IL-22/sIL-22R1, cmvIL-10/sIL-10R1, and
L2
IL10R2 IL10R1 IL22R1
L3
Cle 3/5
Cle 2/3
L2 L2
L5 L3
L5
L3
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90° 90° 90°
Cle 2/3 
Figure 2. Unique Clefts Identified in sIL-10R2
The structures of sIL-10R2, sIL-10R1, and sIL-22R1 are shown as molecular
surfaces. Images in the top row are oriented as in Figure 1A. The surfaces
are colored by atom type with oxygens in red, nitrogens in blue, and sulfurs
in orange. Carbons are colored yellow, green, and purple in sIL-10R2,
sIL-10R1, and sIL-22R1, respectively. Numbers on the surfaces correspond
to loop positions.
Structure
Mechanism of Receptor Sharing by IL-10R2hIL-10/sIL-10R1 crystal structures (Jones et al., 2002, 2008;
Josephson et al., 2001). Top ranked sIL-10R2 docking solutions,
consistent with the mutagenesis data, were identified for IL-
22/sIL-22R1 and cmvIL-10/sIL-10R1 complexes. However,
sIL-10R2 docking to the hIL-10/sIL-10R1 complex was unsuc-
cessful (Table S2 and Figure S6).
IL-22/sIL-22R1/sIL-10R2 and cmvIL-10/sIL-10R1/sIL-10R2
TCs are assembled from threemajor interaction surfaces labeled
site 1, site 2, and site 3 (Figures 4 and 5; Tables S3 and S4). Site 1
forms the high affinity cytokine/R1 contact surface, which is
identical to what has been previously described for the IL-22/
sIL-22R1 and cmvIL-10/sIL-10R1 BCs (Bleicher et al., 2008;
Jones et al., 2002, 2008). The sIL-10R2 binding site 2 is centered
on cytokine helices A and D, but also consists of receptor-
receptor contacts in the cmvIL-10 TC (Figures 4 and 5). Site 3
is formed from contacts between R1 and sIL-10R2 D2 domains
near the C termini of the receptors and in close proximity to the
cell membrane (Figures 4 and 5). While the overall structures of
the IL-22 and cmvIL-10 TCs are similar, contacts in the site 2
and site 3 interfaces are considerably different as reflected in
the sIL-10R2 binding data (Figure 3).Structure 18,IL-22/sIL-22R1/sIL-10R2 Complex
The IL-22/sIL-22R1/sIL-10R2 site 2 interface (910 A˚2) is formed
exclusively between IL-22 and sIL-10R2. The major feature
of site 2 is the protruding IL-22 ‘‘knob’’ surface formed by
Y51IL-22, which is sandwiched between Y82sIL-10R2 and
W143sIL-10R2 in the sIL-10R2 L3/L5 cleft (Figure 4C). L5sIL-10R2
does not contact sIL-22R1 in the TC but is positioned adjacent
to glycosylated helix A residue N54IL-22. This creates an opening
between sIL-22R1 and sIL-10R2 for the N54IL-22-linked carbohy-
drate without disrupting complex formation (Figure 4A). N54IL-22
and R55IL-22 form interactions with L5sIL-10R2 residues
E141sIL-10R2 and E139sIL-10R2, respectively (Figure 4C; Table S3).
Interactions made by Y82sIL-10R2, W143sIL-10R2, Y51IL-22, and
N54IL22 in the IL-22 TC provide an explanation for why these
residues are critical for sIL-10R2 recognition of IL-22/sIL-22R1
(Figure 3). To further characterize the validity of model, IL-22
mutants described by Logsdon et al. (2004) were evaluated for
their ability to activate STAT3 in human HepG2 liver cells, which
express human IL-22R1 and IL-10R2 chains (Figure 4E). These
studies reveal that Y51IL-22, N54IL-22, R55IL-22, and to a lesser
degree E117IL-22 are most important for activating IL-22 STAT3
activity in these cells. The biological activity data further sup-
ports the contacts observed in the IL-22 TC model (Figure 4),
which includes main chain and side chain interactions between
E117IL-22 and K81sIL-10R2 in the L3/L5 cleft (Figure 4C).
The site 3 interface (315 A˚2) occurs between b strand C’ and
the CC’ loop on sIL-22R1 (residues 173–178) and b strands B
and E on sIL-10R2 (Figure 4D). The carbohydrate, attached to
N172sIL-22R1, is also important in site 3 because it stabilizes the
CC’ loop for sIL-10R2 binding. When the carbohydrate attached
to N172sIL-22R1 is removed, crystallographic studies reveal that
CC’ loop residues 172–175, which contact sIL-10R2 in our
model, become disordered (Bleicher et al., 2008). Although
carbohydrate was not included in the docking experiments, it
fits nicely between sIL-22R1 and sIL-10R2 D2 domains, sug-
gesting it might also participate in sIL-22R1/sIL-10R2 site 3 inter-
actions (Figure 4D). Y173sIL-10R2, the only site 3 residue to signif-
icantly disrupt sIL-10R2 binding to IL-22/sIL-22R1, buries 89 A˚2
of surface area and participates in two hydrogen bonds with
E168sIL-22R1 and H179sIL-22R1. Other sIL-10R2 site 3 residues
tested by mutagenesis (Q119A, H128A, R130A, L132A, and
K135A) form less extensive site 3 contacts and do not disrupt
sIL-10R2 binding.cmvIL-10/sIL-10R1/sIL-10R2 Complex
The cmvIL-10 TC site 2 and site 3 interfaces bury 1172 A˚2 and
368 A˚2 of accessible surface area, respectively (Figure 5). In
contrast to the IL-22 TC, sIL-10R2 (L5sIL-10R2) is positioned
adjacent to the cmvIL-10/sIL-10R1 interface. As a result,
receptor-receptor contacts in the cmvIL-10 TC are more than
double (705 A˚2) the size of those in the IL-22 TC (315 A˚2). The
increase is largely due to L5sIL-10R2 residues Y140sIL-10R2 and
E141sIL-10R2, which bury 121 A˚2 and 78 A˚2 of buried surface
area, respectively, into the cmvIL-10 helix A/sIL-10R1 interface
(Figure 5C). This structural feature provides an explanation for
the importance of Y140sIL-10R2 in cmvIL-10/sIL-10R1 and
hIL-10/sIL-10R1 recognition, while it does not contribute to
IL-22/sIL-22R1 binding (Figure 3).638–648, May 12, 2010 ª2010 Elsevier Ltd All rights reserved 641
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Figure 3. Binding Analysis of sIL-10R2
Alanine Mutants by SPR
(A) Relative binding of sIL-10R2 alanine mutants to
IL-22/IL-22R1 (red), cmvIL-10/IL-10R1 (cyan), and
hIL-10/IL-10R1 (black) BCs. sIL-10R2 mutant
binding is presented in normalized RUs relative
to WT sIL-10R2 binding at concentrations of
150 mM. Results are expressed as the mean of
multiple measurements ± standard deviation.
(B and C) Residues tested for binding to IL-22/
sIL-22R1 (B) and cmvIL-10/IL-10R1 (C) are map-
ped onto sIL-10R2 surfaces and colored accord-
ing to the y axis in (A). See also Figures S3–S5.
Structure
Mechanism of Receptor Sharing by IL-10R2There is no protruding knob, corresponding to Y51IL-22, in
cmvIL-10. Thus, few contacts are formed between the
sIL-10R2 L3/L5 cleft and cmvIL-10. However, more extensive
interactions are made between the sIL-10R2 L2/L3 cleft and
cmvIL-10 helix D (Figure 5B). The L2/L3 cleft interactions are
centered on Y56sIL-10R2, which forms a hydrogen bond with the
main chain oxygen of T89cmvIL-10. Consistent with the structural
model, the mutagenesis data demonstrates that Y56sIL-10R2 is
critical for binding to the cmvIL-10/sIL-10R1 complex, but not
to IL-22/sIL-22R1 (Figure 3; Figures S3 and S4). Despite differ-
ences in the interactions of Y56sIL-10R2 and Y140sIL-10R2, some
contacts in the IL-22 and cmvIL-10 TCs are conserved. First,
Y82sIL-10R2, located in the center of site 2, packs against
R22cmvIL-10, between helices A and D, in essentially the same
position as observed in the IL-22 TC (Figure 5C). In addition,
energetically important binding residues Y59sIL-10R2 and
R60sIL-10R2, located at the tip of L2sIL-10R2, form similar contacts642 Structure 18, 638–648, May 12, 2010 ª2010 Elsevier Ltd All rights reservedin both TCs. Y59sIL-10R2 packs against
helix D and R60sIL-10R2 is positioned to
form salt bridges with the conserved
helix C residues E74cmvIL-10 and E101IL-22
(Figures 4B and 5B).
The amount of surface area buried
in the cmvIL-10 TC site 3 (368 A˚2) is
similar to the IL-22 TC (315 A˚2). However,
sIL-10R1 site 3 residues are donated
from three b strands (C, C’, and E) rather
than one (C’) in the IL-22 TC. This is
caused by the different D1/D2 interdo-
main angles of sIL-10R1 compared to
sIL-22R1 (Figure 1B; Figure S2). In
contrast to the tightly clustered site 3 resi-
dues in the IL-22 TC, site 3 contacts in the
cmvIL-10 TC are dispersed over the
entire surface with no obvious energeti-
cally important interaction to stabilize
the complex.
The crystal structure of the cmvIL-10/
sIL-10R1 complex revealed cmvIL-10
forms a cysteine-linked dimer that binds
two sIL-10R1 chains (Jones et al., 2002).
As a result, the cell surface receptor
complex presumably consists of two
IL-10R1 and two IL-10R2 chains. Amodelof this complex was generated by superimposing two docking
models (Figure 5A) onto the dimeric cmvIL-10/sIL-10R1 complex
(Figure 5E). In the resulting complex, the 2-fold-related IL-10R1
and IL-10R2 chains are separated at their C termini by 107 A˚
and 122 A˚, respectively, and do not form contacts with one
another (i.e., they are independent). The space between the
two R1/R2 heterodimers is presumably occupied by the intracel-
lular kinases JAK1 and TYK2, which associate with IL-10R1 and
IL-10R2, respectively (Finbloom andWinestock, 1995). For each
R1/R2 heterodimer, the spacing between the C termini of the D2
domains is 23 A˚ (Table S2). Furthermore, the C terminus of the
IL-10R2 (last residue in D2, T194sIL-10R2) is positioned 9 A˚
higher, relative to the putative position of the membrane, than
the equivalent residue in sIL-10R1 (L205sIL-10R1). Similar D2
asymmetries have been observed in the growth hormone
receptor complex and other TCs (de Vos et al., 1992; Wang
et al., 2009). The asymmetry is proposed to be induced by
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Figure 4. IL-22 Ternary Complex
(A) Overall structure of the IL-22 TC.
(B) Site 2 interactions between helix D and the
L2/L3 cleft.
(C) Site 2 interactions between helix A and the
L3/L5 cleft.
(D) Site 3 contacts.
(E) Anti-phospho-STAT3 western blot from lysates
prepared from HepG2 cells stimulated with IL-22 or
IL-22mutants.SeeAlsoFigureS6andTablesS1–S4.
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Mechanism of Receptor Sharing by IL-10R2cytokine binding, which provides a structural mechanism by
which JAK kinase activation may occur (Brown et al., 2005).
hIL-10/sIL-10R1/sIL-10R2 Ternary Complex
In contrast to docking studies performed with IL-22/sIL-22R1
and cmvIL-10/sIL-10R1, a high quality docking solution was
not obtained using the hIL-10/sIL-10R1 complex. Additional
computational studies were performed to try to determine why
the docking failed. For example, was it due to subtle conforma-
tional differences in sIL-10R1s in the hIL-10/sIL-10R1 and
cmvIL-10/sIL-10R1 BCs? To answer this question, sIL-10R1
from the cmvIL-10/sIL-10R1 structure was used to form a hybrid
hIL-10/sIL-10R1cmv complex. However, a better docking
solution was not obtained using this hybrid complex. In addition,
docking studies were performed using an entire hIL-10 dimer
and one sIL-10R1 chain to ensure the entire sIL-10R2 binding
epitope was included in the experiment. However, these exper-
iments were also unsuccessful.
Despite the inability to obtain a de novo docking solution,
structural similarity between cmvIL-10/sIL-10R1 and hIL-10/
sIL-10R1 complexes (e.g., half of the dimeric complexes), andStructure 18, 638–648, May 12, 2010similar binding properties of sIL-10R2
mutants for both complexes (Figure 3),
suggest that sIL-10R2 contacts hIL-10/
sIL-10R1 in essentially the same manner
as observed in the cmvIL-10 TC. Based
on these observations, a ‘‘best’’ hIL-10
TC model was generated by superposi-
tion of hIL-10/sIL-10R1 onto the cmvIL-
10 TC. Contacts made by sIL-10R2 in
this hIL-10 TC model support current
and prior hIL-10 mutagenesis studies.
In particular, the most important residue
identified for the hIL-10/sIL-10R2 interac-
tion is M22hIL-10 (Yoon et al., 2006), which
packs against similarly important
Y82sIL-10R2 in the hIL-10 TC. Additional
hIL-10 and sIL-10R2 residues important
for sIL-10R2 binding that form putative
hydrogen bonds in the hIL-10 TC include
N21hIL-10/W143sIL-10R2, R32hIL-10/
S78sIL-10R2, and S93hIL-10/Y56sIL-10R2.
DISCUSSION
This study was initiated to understand
the molecular mechanisms that allowthe sIL-10R2 common chain to promiscuously bind to at least
five different class 2 cytokines, which induce diverse cellular
activities. The questions we sought to address were: (a) what
are the structural features of sIL-10R2 that facilitate promis-
cuous binding? (b) Does sIL-10R2 form energetically and struc-
turally identical, or distinct, interactions when engaging different
binding partners? In addition to determining the molecular
basis for promiscuous low affinity protein-protein interactions
(14–250 mM), for which there is a paucity of literature, these
studies also have implications for interpreting IL-10R2 SNPs,
which cause human disease. In particular, SNPs in sIL-10R2
result in numerous pathologies including early-onset colitis
(Glocker et al., 2009) and persistent HBV infection (Frodsham
et al., 2006). Several more IL-10R2 SNPs have been identified
in patients with inflammatory bowel disease (C. Klein, personal
communication), which further argues for the need to under-
stand the structure and mechanism of IL-10R2 binding.
High affinity interactions between hIL-10/sIL-10R1, cmvIL-10/
sIL-10R1, and IL-22/sIL-22R1 BCs depend on a conserved L2
loop tyrosine, which inserts itself into a cleft between helices A
and B on the respective cytokines (Figure 1D). This paradigmª2010 Elsevier Ltd All rights reserved 643
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Figure 5. cmvIL-10 Ternary Complex
(A) Overall structure of the cmvIL-10 TC.
(B) Site 2 interactions between helix D and the
L2/L3 cleft.
(C) Site 2 interactions between helix A and the
L3/L5 cleft.
(D) Site 3 contacts.
(E) Dimeric cmvIL-10 signaling complex. See also
Figure S6 and Tables S1–S4.
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Mechanism of Receptor Sharing by IL-10R2is reversed for sIL-10R2, which forms L2/L3 and L3/L5 clefts
(Figure 2) that selectively recognize protruding surfaces on helix
DcmvIL-10, hIL-10 and helix AIL-22, respectively (Figures 4 and 5).
Thus, sIL-10R2 site 2 recognition is largely defined by the distinct
interhelix angles, between helices A and D, found in the different
cytokines (Presnell and Cohen, 1989; Walter, 2004) (Figures 4A
and 5A). Additional contacts are made by tyrosine, arginine, and
glutamate residues located at the tips of L2sIL-10R2 and L5sIL-10R2.
While the sIL-10R2 clefts provide the ability to recognize
distinct cytokine features, Y82sIL-10R2 appears to be the common
sIL-10R2 epitope required for interaction with each binary
receptor complex, much like the conserved L2 tyrosine of
sIL-10R1 and sIL-22R1 is highly conserved and required for644 Structure 18, 638–648, May 12, 2010 ª2010 Elsevier Ltd All rights reservedhigh affinity IL-22 and IL-10 interactions
(Figure 1D). Interestingly, prior structure
function studies on the shared receptors
gp130 and gc have shown that aromatic
residues (F169gp130 and Y103gc) form
conserved contacts in the center of the
IL-6/gp130, IL-2/gc, and IL-4/gc inter-
faces (Wang et al., 2009). Superposition
of the D1 domain of sIL-10R2, with
gp130 and gc, reveals that L3 Y82sIL-10R2
is structurally conserved with F169gp130
and Y103gc (Figure 6A). Furthermore,
superposition of IL-6 from the IL-6/IL-6R/
gp130 structure and IL-22 from the
IL-22/sIL-22R1/sIL-10R2 model reveals
that Y82sIL-10R2 and F169gp130 are sepa-
rated by 4 A˚ (Ca atoms) in their respective
complexes (Figure 6B). This result pro-
vides additional independent data to
confirm the IL-22 TC model (Figure 4)
and suggests that the structurally con-
served L3 aromatic residues (Tyr or Phe)
form the critical common binding epitope
used by the shared cytokine receptors
gp130, IL-2gc, and IL-10R2 to recognize
diverse cytokine surfaces. Mutation of
F169gp130 and Y103gc functionally dis-
rupts receptor-ligand interactions and
subsequent cell signaling (Kurth et al.,
1999; Middleton et al., 1996). Together,
these data suggest Y82sIL-10R2 is critical
for sIL-10R2 function and hints at a
common origin of promiscuous shared
cytokine receptors.In addition, Olosz and Malek (2000) pointed out that Y103gc is
structurally conserved with the erythropoietin receptor (EPOR)
residue, F93. However, the position of F93EPOR has diverged sig-
nificantly from the tight cluster of common chain aromatic resi-
dues shown in Figure 6A (Figure S7). Nonetheless, it is notable
that F93EPOR is found in the interface of the EPO/EPOR complex
(Syed et al., 1998) and in the interface of the EPOR dimer struc-
ture, which presumably mimics the unbound EPOR cell surface
complex (Livnah et al., 1999). In contrast to IL-10R2, gp130,
and gc, EPOR, as well as the growth hormone receptor (GHR),
form homodimeric receptor complexes (e.g., 1:2 EPO/EPOR or
GH/GHR; de Vos et al., 1992; Syed et al., 1998). GHR also
contains a functionally critical aromatic residue in its L3 chain
L5
A
Y82
B
R55 F169
Y82
Y51
Figure 6. Common Binding Epitope Identi-
fied between the Promiscuous Shared
Cytokine Receptors
(A) Superposition of sIL-10R2 (yellow), gp130
(magenta), and gc chain (green). The inset shows
the structural similarity of L3 loop residues
Y82sIL-10R2, F169gp130 (F191gp130 in Uniprot data-
base P40189), and Y103gc. EPOR and the GHR
also have aromatic L3 residues (F93EPOR and
W104GHR), which have diverged from the struc-
tural alignment shown in Figure 6A. See also
Figure S7.
(B) The positions of Y82sIL-10R2 and F169gp130 are
conserved in their respective TCs. Ribbon diagram
of the IL-22 TC model (Figure 4) with IL-22/sIL-
22R1 colored cyan and sIL-10R2 colored yellow.
IL-6 from the IL-6/IL-6R/gp130 complex (PDB
1P9M; Boulanger et al., 2003) was superimposed
onto IL-22 from the IL-22 TC model (Figure 4)
and the position of gp130 (green) is shown. The
inset shows IL-22 residues Y51IL-22 and R55IL-22
along with Y82sIL-10R2 (yellow) and F169gp130
(magenta).
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Mechanism of Receptor Sharing by IL-10R2(W104GHR; Clackson and Wells, 1995), but its position has
diverged even further away from Y82sIL-10R2 than F93EPOR
(Figure S7). This suggests L3 aromatic residues are generally
critical for recognition of diverse class 1 and class 2 cytokines.
However, EPOR and GHR, which must form high and low affinity
binding interfaces, presumably require greater structural diver-
sity in the positions of their aromatic residues (F93EPOR and
W104GHR) than the specialized common chain receptors
(IL-10R2, gp130, and gc), which only form promiscuous low
affinity contacts.
Since IL-10R2 activates multiple cytokine complexes, the
cellular phenotype of an IL-10R2 SNP can be caused by disrupt-
ing the function of one or more cytokines. Thus, we sought to
determine if sIL-10R2mutants will have the same binding pheno-
type in each complex. Our studies found select sIL-10R2
residues (Y56sIL-10R2, Y140sIL-10R2, and W143sIL-10R2) have
distinct energetic functions in the IL-22 and cmvIL-10/hIL-10
TCs (Figure 3; Figure S5). This result suggests specific
sIL-10R2 SNPs could selectively disrupt IL-10 or IL-22 signaling
and suggests caution should be applied in attributing biological
outcomes to specific cytokines. Additional studies will beStructure 18, 638–648, May 12, 2010required to characterize how IL-26 and
IL-28/IL-29 are recognized by IL-10R2.
The studies reported here have
focused on sIL-10R2 residues directly
involved in cytokine and R1 chain recog-
nition. However, other mechanisms that
disrupt IL-10R2 function are possible.
For example, the K47EsIL-10R2 SNP,
which is associated with failure to clear
HBV, has been shown to increase
IL-10R2 expression levels on cells (Frod-
sham et al., 2006). Consistent with this
interpretation, we found E47sIL-10R2 and
K47sIL-10R2 had no impact on sIL-10R2
binding to IL-22/sIL-22R1 (data notshown). From a structural perspective, K47sIL-10R2 is considered
the preferred residue since it forms a salt bridge with E96sIL-10R2,
which would be disrupted when replaced with a glutamate
residue (Figure 1E). How thismutation increases IL-10R2 surface
expression remains unknown.
Akey feature of IL-10R2promiscuity is its very lowaffinity for the
cellular cytokine complexes that it activates. This presents tech-
nical challenges that have, to date, prevented crystal structure
analysis of the class 2 cytokine TCs. To overcome this problem,
we used computational docking studies to generate IL-22 and
cmvIL-10 TC models. Although not crystal structures, these
models provide clear molecular explanations for how sIL-10R2
distinctly recognizes IL-22 and IL-10 BCs, which are consistent
withexperimental data.However,with thecurrentdockingparam-
eters, we failed to generate an independent hIL-10 TC model.
Interestingly, the success, or failure, of the docking experiments
correlates with sIL-10R2 affinity for IL-22/sIL-22R1 (14 mM),
cmvIL-10/sIL-10R1 (80 mM), and hIL-10/sIL-10R1 (250 mM)
BCs (Logsdon et al., 2004; Yoon et al., 2005). This suggests that
successful sIL-10R2 docking requires a Kd of at least 100 mM
using the current docking parameters and restraints.ª2010 Elsevier Ltd All rights reserved 645
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Mechanism of Receptor Sharing by IL-10R2In summary, our structural, biochemical, modeling, and
activity data provide novel insights into the promiscuous binding
of the IL-10R2 common chain. In particular, the studies demon-
strate that despite being a shared weak-binding receptor,
sIL-10R2 residues make distinct energetic and structural contri-
butions to binding. This provides a molecular frame work to
characterize additional IL-10R2 SNPs and might be used to
design protein therapeutics that restore one or more cytokine
activities in patients with defective IL-10R2 signaling complexes.
EXPERIMENTAL PROCEDURES
Expression and Purification of sIL-10R2
For crystallization, sIL-10R2, with mutations N49Q, N68Q, N102Q, and N161Q
(sIL-10R2NQ), and sIL-10R2NQ C106S/S126C were expressed in insect cells
as C-terminal his6 fusion proteins. Mutagenesis was performed using Quik-
Change site-directed mutagenesis kit (Stratagene). sIL-10R2 was purified by
nickel affinity chromatography and the his6 tag was removed using Factor
Xa protease (Novagen). The cleaved protein was further purified by anion
exchange chromatography (Poros HQ/H 10/100) and gel filtration chromatog-
raphy using Superdex 200 HR 10/30 columns.
For selenomethionine incorporation, pET-21a plasmid sIL-10R2NQ C106S
was transformed into E. coli strain B834 (DE3) (Novagen). Cells were grown
using M9 SeMet high yield growth medium (Medicilon) at 37C to OD600 =
0.6, and protein expression was induced with 1mM IPTG for 8 hr. sIL-10R2NQ
C106S inclusion bodies were purified and solubilized as previously described
(Yoon and Walter, 2007). Solubilized sIL-10R2NQ C106S was refolded by
rapid 10-fold dilution in refolding buffer containing 50 mM NaCl, 100 mM
Tris-HCl (pH 8.0), 2.5 mM EDTA, 0.2 mM oxidized glutathione, 2 mM reduced
glutathione, and 600 mM arginine and purified as described above.
Crystallization and Data Collection
sIL-10R2NQ C106S/S126C and SeMet-sIL-10R2NQ C106S proteins were
concentrated to 10 mg/ml in 20 mM Tris (pH 8.0) and 150 mM NaCl and
crystallized by hanging drop vapor diffusion methods with 0.95 M Li2SO4
and 0.1 M HEPES (pH 7.5). Crystals were placed into cryoprotectant consist-
ing of 20% glycerol, 1.4 M Li2SO4, and 0.1 M HEPES (pH 7.5) and flash frozen
under a N2 gas stream at 100 K. X-ray diffraction data were collected at the
Advance Photon Source (SER-CAT ID22 beamline). All data were processed
with HKL2000 (Otwinowski and Minor, 1997).
Structure Determination and Refinement
Single-wavelength anomalous diffraction data were collected on a single
crystal of SeMet-sIL-10R2NQ C106S (Table 1, crystal 1) and SeMet positions
were identified using the program SOLVE (Terwilliger and Berendzen, 1999).
The resulting phaseswere combinedwith structure factor amplitudes obtained
from sIL-10R2NQ C106S/S126C crystal (Table 1, crystal 2) and refined by
solvent leveling/flipping using CNS version 1.1 (Abrahams and Leslie, 1996;
Brunger et al., 1998). The sIL-10R2 model was built automatically using
ARPwARP implemented in the CCP4i suite (CCP4, 1994; Lamzin and Wilson,
1993; Perrakis et al., 1997) and refinement was completed using CNS version
1.1 (Brunger et al., 1998).
SPR Experiments
All sIL-10R2 proteins used for SPR studies (WT and mutants) contained the
same NQ mutations as sIL-10R2NQ used for structure determination. Each
protein was expressed and purified as previously described (Logsdon et al.,
2002). SPR data were obtained using a Biacore 2000 as previously described
(Logsdon et al., 2004; Yoon et al., 2005, 2006), except sIL-10R2, sIL-22R1, and
sIL-10R1 were simultaneously injected over cytokines amine coupled to CM-5
sensor chips. IFN-t4 (control surface), IL-22, cmvIL-10, and hIL-10 were
coupled at final surface densities of 280-293RU, 220-274RU, 237-291RU,
and 601-823RU, respectively. Maximal sIL-10R2 binding, in response units
(RUs), was determined by subtracting a baseline response obtained by inject-
ing 1 mM sIL-10R1 and 500 nM sIL-22R1 over the chip surface (Figure S3).
Additional injections contained 1 mM sIL-10R1, 500 nM sIL-22R1, and646 Structure 18, 638–648, May 12, 2010 ª2010 Elsevier Ltd All right150 mMsIL-10R2 or sIL-10R2mutant (Supplemental Experimental Procedures
and Figures S3 and S4). An additional 25 mM sIL-10R2 concentration was also
tested with equivalent results (Figure S5). Absolute RUs were normalized to
WT sIL-10R2. All sIL-10R2 mutants were tested at least twice. The error in
the assay was determined by comparing ten different WT sIL-10R2 experi-
ments and also by evaluating replicates of the sIL-10R2 mutants. Both
analyses revealed equivalent overall errors of 7%, 10%, and 23% for IL-22,
cmvIL-10, and hIL-10 chip surfaces, respectively.
HADDOCK Docking Experiments
Docking studies were performed using the program HADDOCK (Dominguez
et al., 2003) running on the UAB Cheaha computing grid (http://docs.
uabgrid.uab.edu/wiki/Cheaha). Experiments consisted of rigid body docking
of 1000 possible solutions evaluated using 180 sampling. The top 200
solutions were subjected to semi-flexible simulated annealing using CNS for
atoms within 5 A˚ of the interfaces (van Dijk et al., 2006). Finally, flexible explicit
solvent refinement was performed to provide a final ranking of the solutions
(van Dijk and Bonvin, 2006). Default energetic, refinement, and scoring param-
eters were used for all runs. Ambiguous interaction restraints (Table S1, AIRs)
were chosen based on hIL-10 (Yoon et al., 2006), IL-22 (Logsdon et al., 2004;
Wolk et al., 2004; Wu et al., 2008), and sIL-10R2 mutagenesis studies
(Figure 3). Unambiguous restraints were applied to each Ca atom in the binary
IL-22/sIL-22R1, hIL-10/sIL-10R1, and cmvIL-10/sIL-10R1 complexes result-
ing in 342 to 349 additional restraints. Solutions were clustered using an
rmsd cut-off of 7.5 A˚ and evaluated graphically with PYMOL (DeLano, 2002).
Buried surface areas were calculated with NACCESS (Hubbard and Thorton,
1993). Superpositions were performed by STAMP (Russell and Barton, 1992)
as implemented in VMD (Humphrey et al., 1996).
Stat3 Activity Assay
Human hepatoma HepG2 cells (American Type Culture Collection) were
cultured in serum-free Eagle’s minimal essential medium overnight followed
by stimulation with IL-22 or IL-22 mutants (10 ng/ml) for 30 min. Cells were
then washed with cold phosphate buffered saline and lysed, and protein
extracts (30 mg) were prepared and used for western blot analyses using
anti-phospho-STAT3 (Tyr705) antibodies (Cell Signaling Technology).
ACCESSION NUMBERS
The coordinates for the structure of IL-10R2 have been deposited in the protein
databank with the accession number 3LQM.
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